Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up visits have been completed in its Phase 2b clinical study of oral Prurisol in moderate-to-severe chronic plaque psoriasis. Prurisol is being developed as a novel, nonbiologic, orally-delivered psoriasis drug candidate.

All patient follow up visits completed. I took that as a successesful completion. We are still waiting results yes.